Karyopharm Therapeutics Inc. (NASDAQ:KPTI) is a biopharmaceutical company focused on developing innovative cancer therapies. On February 26, 2025, KPTI will undergo a reverse stock split at a ratio of 15-for-1. This strategic move is designed to consolidate shares, effectively increasing the per-share market price of KPTI's common stock.
The reverse stock split, approved by Karyopharm's stockholders on January 30, 2025, aims to help the company meet the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. As highlighted by PR Newswire, the split will take effect at 5:00 p.m. Eastern Time on February 25, 2025, with trading on a split-adjusted basis commencing the following day.
Currently, KPTI's stock price is $0.57, reflecting a decrease of 4.10% with a change of -$0.02. The stock has fluctuated between a low of $0.55 and a high of $0.60 today. Over the past year, KPTI has experienced significant volatility, with a high of $25.50 and a low of $0.55.
Karyopharm's market capitalization is approximately $72.1 million, and the trading volume for KPTI is 1,330,711 shares on the NASDAQ exchange. The reverse stock split is expected to positively impact the stock's market performance by increasing its per-share price, potentially attracting more investors and stabilizing its market position.
